Buserelin is a luteinising-hormone-releasing-hormone (GnRH) agonist; in nine men with advanced prostate cancer, LH first rose and then fell, and testosterone dropped to castrate levels within three weeks and stayed there for 24 weeks.
fact added identity: CAS registry number 57982-77-1. · 2026-09-27 12:04 · somebody
fact added summary: Buserelin is a luteinising-hormone-releasing-hormone (GnRH) agonist; in nine men with advanced prostate cancer, LH first · 2026-09-27 12:04 · somebody
fact added summary: In a Japanese phase III trial in 271 women with endometriosis, oral dienogest relieved pain as well as intranasal busere · 2026-09-27 12:04 · somebody
citation added pmid 6122893 cited as emerging: Buserelin produced sustained castrate testosterone levels in advanced prostate cancer · 2026-09-27 12:04 · somebody
citation added pmid 18653184 cited as established: Dienogest matched intranasal buserelin for endometriosis pain with less bone loss (phase III RCT) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.